Valuation: Innoviva, Inc.

Market Cap 1.48B 1.32B 1.23B 1.12B 2.11B 142B 2.13B 14.86B 5.76B 72.78B 5.56B 5.44B 234B P/E 2026 *
9.18x
P/E 2027 * 9.06x
Enterprise Value 955M 849M 792M 722M 1.36B 91.82B 1.37B 9.58B 3.71B 46.94B 3.59B 3.51B 151B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 1.57x
Free-Float
98.99%
Yield 2026 *
-
Yield 2027 * -
1 day-0.24%
1 week-1.16%
Current month-3.35%
1 month-3.98%
3 months-8.11%
6 months-10.83%
Current year+2.55%
1 week 20.5
Extreme 20.495
21.45
1 month 20.23
Extreme 20.23
21.51
Current year 19
Extreme 19
25.14
1 year 16.52
Extreme 16.52
25.14
3 years 12.22
Extreme 12.22
25.14
5 years 10.64
Extreme 10.64
25.14
10 years 7.58
Extreme 7.58
25.14
Manager TitleAgeSince
Chief Executive Officer 42 19/05/2020
Director of Finance/CFO 60 20/08/2023
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 75 11/02/2018
Director/Board Member 66 11/02/2018
Director/Board Member 42 18/05/2025
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Tax

Controller/Auditor

-1,127 0.0015%
20/08/26 Tax

Chief Executive Officer

-1,130 0.0015%
20/08/26 Tax

Chief Financial Officer

-558 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-0.24%-1.16%+17.28%+58.79% 1.48B
-0.61%-3.43%+36.07%+117.61% 1,019B
-1.02%-5.60%+35.72%+64.82% 617B
+1.11%-0.58%+12.36%+78.27% 464B
+0.34%-3.01%+61.79%+41.79% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+54.42% 218B
-1.87%-4.10%+28.44%+97.54% 179B
Average -0.71%-3.17%+25.19%+58.89% 369.87B
Weighted average by Cap. -0.60%-3.32%+29.07%+71.15%

Financials

2026 *2027 *
Net sales 451M 401M 374M 341M 643M 43.38B 649M 4.53B 1.75B 22.18B 1.69B 1.66B 71.18B 490M 435M 406M 370M 699M 47.11B 705M 4.92B 1.91B 24.08B 1.84B 1.8B 77.29B
Net income 179M 159M 149M 135M 255M 17.23B 258M 1.8B 697M 8.81B 673M 658M 28.26B 175M 155M 145M 132M 249M 16.78B 251M 1.75B 679M 8.58B 655M 641M 27.53B
Net Debt -526M -467M -436M -398M -750M -50.56B -757M -5.28B -2.05B -25.85B -1.97B -1.93B -82.95B -712M -633M -590M -538M -1.01B -68.44B -1.02B -7.14B -2.77B -34.99B -2.67B -2.62B -112B
Logo Innoviva, Inc.
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial.
Employees
159
Date Price Change Volume
02/10/26 US$20.50 -0.24% 774,706
01/10/26 US$20.55 -3.11% 927,091
30/09/26 US$21.21 +0.47% 1,100,217
29/09/26 US$21.11 -0.57% 555,807
28/09/26 US$21.23 +2.36% 854,634
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
20.50USD
Average target price
35.00USD
Spread / Average Target
+70.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INVA Stock